257 related articles for article (PubMed ID: 15061827)
1. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
3. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
[TBL] [Abstract][Full Text] [Related]
4. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
5. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine in Alzheimer disease: efficacy over two years.
Grossberg G; Irwin P; Satlin A; Mesenbrink P; Spiegel R
Am J Geriatr Psychiatry; 2004; 12(4):420-31. PubMed ID: 15249280
[TBL] [Abstract][Full Text] [Related]
7. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
[TBL] [Abstract][Full Text] [Related]
8. [Rivastigmine: a review of its clinical effectiveness].
Spiegel R
Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
[TBL] [Abstract][Full Text] [Related]
12. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
Muhlack S; Przuntek H; Müller T
Pharmacopsychiatry; 2006 Jan; 39(1):16-9. PubMed ID: 16453249
[TBL] [Abstract][Full Text] [Related]
13. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.
Desai A; Grossberg G
Expert Opin Pharmacother; 2001 Apr; 2(4):653-66. PubMed ID: 11336614
[TBL] [Abstract][Full Text] [Related]
14. Does rivastigmine improve cognitive functions or disability in patients with Alzheimer's disease?
Cantisani TA; Celani MG; Righetti E
Neuroepidemiology; 2004; 23(4):209-10. PubMed ID: 15272224
[No Abstract] [Full Text] [Related]
15. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Darreh-Shori T; Hellström-Lindahl E; Flores-Flores C; Guan ZZ; Soreq H; Nordberg A
J Neurochem; 2004 Mar; 88(5):1102-13. PubMed ID: 15009666
[TBL] [Abstract][Full Text] [Related]
16. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
17. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
[TBL] [Abstract][Full Text] [Related]
18. Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients.
Chou MC; Chen CH; Liu CK; Chen SH; Wu SJ; Yang YH
J Alzheimers Dis; 2012; 31(4):857-64. PubMed ID: 22751168
[TBL] [Abstract][Full Text] [Related]
19. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
20. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
